Online citations, reference lists, and bibliographies.
← Back to Search

Diagnostic Value Of Soluble Mesothelin-related Peptides In Pleural Effusion For Malignant Pleural Mesothelioma

Ruiyue Gao, F. Wang, Z. Wang, Yanbing Wu, L. Xu, Y. Qin, H. Shi, Zhaohui Tong
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background: Soluble mesothelin-related peptide (SMRP) is a widely studied tumor marker for diagnosing malignant pleural mesothelioma (MPM). This study discussed the diagnostic value of SMRPs in pleural effusion (PE) for MPM. Methods: Medline, Embase, Web of Science, and Cochrane library system were systematically searched on the data of SMRPs in PE for MPM diagnosis. Pooled diagnostic sensitivity, specificity, and symmetric receiver operating characteristic curve were calculated. Results: Thirteen studies fulfilled the inclusion criteria and a total of 3359 cases including 759 MPM cases, 1061 non-MM (malignant mesothelioma) malignant PE, and 1539 benign PE were brought into this meta-analysis. The pooled results of SMRPs in PE for diagnosing MPM were as follows: sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 0.68 (95% confidence interval [CI]: 0.64–0.72), 0.91 (95% CI: 0.86–0.94), 7.8 (95% CI: 5.0–12.0), 0.35 (95% CI: 0.31–0.40), and 22 (95% CI: 14–35), respectively. The area under the summary receiver operating characteristic curves (AUC) was 0.75 (95% CI: 0.72–0.80). Subgroup analyzes revealed that the AUC of cohort group using histological diagnosis could be improved to 0.86 (95% CI: 0.83, 0.89). The Deek's funnel plot asymmetry test showed no publication bias. Conclusion: Although the sensitivity of SMRPs was low, PE-SMRPs can be a good indicator of the existence of MPM.
This paper references
10.1371/journal.pone.0185850
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center
Takehiro Otoshi (2017)
10.3892/ETM_00000048
Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.
N. Fujimoto (2010)
10.1007/s12032-013-0649-x
Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report
P. Canessa (2013)
10.1159/000468545
Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis
Yuan Yang (2017)
10.1007/s12032-013-0543-6
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA
R. Filiberti (2013)
10.1016/S1470-2045(13)70257-2
Asbestos is not just asbestos: an unrecognised health hazard.
F. Baumann (2013)
10.1186/1471-2288-3-25
The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews
P. Whiting (2003)
10.1155/2014/413946
Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
J. Creaney (2014)
10.1016/j.lungcan.2011.01.011
Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
N. Boudville (2011)
10.1183/09031936.00148211
A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions
C. Hooper (2012)
10.1373/clinchem.2007.096032
Bias in sensitivity and specificity caused by data-driven selection of optimal cutoff values: mechanisms, magnitude, and solutions.
M. Leeflang (2008)
10.1016/j.cca.2014.02.024
Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.
Z. Hu (2014)
10.1111/resp.12517
Asbestos in Asia
Su Lyn Leong (2015)
10.1016/j.jtho.2018.02.021
Progress in the Management of Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1186/1471-2288-11-27
Uptake of newer methodological developments and the deployment of meta-analysis in diagnostic test research: a systematic review
B. Willis (2011)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1074/jbc.M312372200
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion*
A. Rump (2004)
10.1056/NEJMoa1115050
Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
H. Pass (2012)
10.21037/jtd.2017.10.132
Serum mesothelin and other biomarkers: what have we learned in the last decade?
A. Cristaudo (2018)
10.1136/oemed-2017-104298
Estimation of the global burden of mesothelioma deaths from incomplete national mortality data
Chimed-Ochir Odgerel (2017)
10.21037/jtd.2017.11.62
Diagnostic accuracy of tumor markers for malignant pleural effusion: a derivation and validation study.
K. Zhai (2017)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
10.1097/JTO.0b013e31824c9272
CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural Effusions
C. Blanquart (2012)
Research and reporting methods accuracy studies
A Cristaudo (2011)
10.1001/jama.1993.03510170086037
Users' guides to the medical literature.
G. Guyatt (1993)
10.1001/JAMA.271.5.389
Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group.
R. Jaeschke (1994)
10.1016/j.rmed.2009.05.017
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1111/j.1349-7006.2007.00715.x
Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells
C. Sapede (2008)
10.3109/07357907.2012.749265
Evaluation of Soluble Mesothelin-related Peptide as a Diagnostic Marker of Malignant Pleural Mesothelioma Effusions: Its Contribution to Cytology
P. Canessa (2013)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
Clinical signi fi cance of pleural effusion mesothelin in malignant pleural mesothelioma
S Yamada (2008)
10.1136/thoraxjnl-2017-211321
British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I. Woolhouse (2018)
10.1016/j.jtho.2017.04.020
Improving the Accuracy of Mesothelioma Diagnosis in China.
M. Carbone (2017)
10.1136/thoraxjnl-2014-205205
Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
J. Creaney (2014)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1164/rccm.200811-1729OC
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
H. E. Davies (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar